ReviewClinical ophthalmology (Auckland, N.Z.)2025
Retinopathy of Prematurity (ROP): An Overview of Biomarkers in Various Samples for Prediction, Diagnosis, and Prognosis.
Review in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- ScRNA-seq Data Reveal Gene Upregulation and Downregulation in Oxygen-Induced Retinopathy.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- A Potential Gut-Retina Axis in Retinopathy of Prematurity: Emerging Perspectives on Microbiome-Mediated Modulation of the IGF-1-VEGF Pathway.International journal of molecular sciences · 2026Review
- Research progress on the use of beta-blockers in the progression prevention, and treatment of retinopathy of prematurity.Frontiers in pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinopathy of Prematurity (ROP) is a proliferative retinal vascular disease marked by abnormal development of retinal vessels in low birth weight preterm infants. It is one of the leading causes of blindness in preterm infants. Current ROP screening methods impose high demands on both the equipment and the expertise of ophthalmologists, which limits their widespread application, particularly in secondary hospitals and remote areas. Thus, the identification of relevant biomarkers and the development of simpler detection methods are important and promising. Non-invasive or minimally invasive sampling methods, along with biomarkers possessing high sensitivity and specificity, could greatly enhance neonatal screening, facilitate early diagnosis, and improve prevention of blindness in preterm infants. This review provides relevant medical insights for clinical practice. This review explored, compares and analyzes various sampling sources. It compares and analyzes research on ROP-related biomarkers derived from these samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.